Virtual Grand Rounds

Release Date:    Thursday, September 4, 2014
Expiration Date:    Thursday, September 3, 2015
Estimated Time To Complete Activity:    60 minutes

 

Credits: 
1 AMA PRA Category 1 Credit™
1 ANCC contact hour

To participate in this activity, please click on the ‘launch’ button. You will be redirected to RealCME.com. You are invited to participate in this CME/CE-certified virtual grand rounds activity entitled, ”The Breast Cancer Continuum: Intersecting Current and Novel Treatment Strategies In Clinical Practice.”

Fee Statement
There is no fee for this educational activity.

Target Audience
This activity is intended for medical oncologists, surgeons, radiation oncologists, researchers, oncology nurses and other healthcare providers involved in the treatment and management of patients with breast cancer.

Learning Objectives
After completing this activity, the participant will demonstrate the ability to:

  • Analyze key pathologic and molecular findings in the identification and diagnosis of early-stage, locally advanced, and metastatic breast cancers
  • Determine optimal sequencing and duration for individualized treatments for HER2+ patients with MBC
  • Evaluate the benefits of mTOR inhibitors, non-taxane microtubules, epothilones, antibody-drug conjugates, and other agents for MBC
  • Assess the optimal use of hormonal therapy in patients with breast cancer
  • Apply current and emerging evidence supporting VEGF and other targeted therapy in breast cancer treatment
  • Utilize prognostic assays in determining treatments for patients with breast cancer
  • Incorporate current treatment guidelines into decision-making for treating patients with breast cancer


Virtual Grand Rounds Activity Agenda

  • Introduction (5 mins)
  • Component 1: What are some outstanding pathologic and molecular concerns in the diagnosis and treatment of breast cancer? (15 mins)
  • Component 2: How Do We Treat Patients With Early-Stage Breast Cancer? (15 mins)
  • Component 3: What Therapies and Strategies Are Appropriate In Treating Patients with Locally Advanced and Metastatic Breast Cancer? (20 mins)
  • Conclusion (5 mins)

Technical Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 5.0+ for Mac OSX 10.5 and above

For video playback, install the latest version of Flash or Quicktime.

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and AXIS. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within 3 weeks.

Nursing Continuing Medical Education
Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation
This educational activity for 1.0 contact hours is provided by Postgraduate Institute for Medicine.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Edith A. Perez, MD, has no real or apparent conflicts of interest to report.

The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Linda Gracie-King, MS, Deborah Middleton, MS and Diedrea White, BA, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Safeguards Against Commercial Bias
Postgraduate Institute for Medicine and AXIS affirm that the content and format of the CME activities and related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, Postgraduate Institute for Medicine and AXIS employ several strategies to ensure the absence of commercial bias, including, but not limited to, review of all planned content for CME activities jointly sponsored by Postgraduate Institute for Medicine and AXIS to ensure adherence to the Accreditation Council for Continuing Medical Education’s content validation statements, and resolution of any actual or perceived conflicts of interest that exist. We employ three metrics as we review materials:

1.    Fair balance
     a.    Recommendations or emphasis must fairly represent and be based on a reasonable and valid interpretation of the information available on the subject matter
     b.    No single product or service is overrepresented when other equal competing products or services are available for inclusion
2.    Scientific objectivity of studies mentioned in the materials or used as the basis for content
3.    Appropriateness of patient care recommendations made to learners


Jointly provided by

Postgraduate Institute for Medicine and AXIS Medical Education, Inc.

This activity is supported by an independent educational grant from Genentech, Inc.
For further information concerning Genentech grant funding, visit http://www.gene.com/good/grants